Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Lymphoma
•
Hematology
Would you treat patient with early stage unfavorable classic Hodgkin lymphoma with 6 cycles instead of 4 cycles of Nivo-AVD to avoid mediastinal radiation in young female?
Related Questions
Do you ever consider maintenance therapy for patients with relapsed mantle cell lymphoma post CAR-T therapy?
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
How have the results of the SUNMO trial with mosunetuzumab/polatuzumab vedotin impacted your treatment choices for transplant ineligible relapsed/refractory DLBCL?
How would you approach treatment with BV-CHP regimen in a patient with newly diagnosed CD30+ ALK- anaplastic large cell lymphoma at high risk for cardiotoxicity?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
How do you approach patient with CLL/SLL limited to the prostate?
For patients with relapsed/refractory follicular lymphoma receiving mosunetuzumab, when, if ever, would you consider transitioning from intravenous to subcutaneous administration?
Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
What is your preferred treatment regimen for a patient with R/R cutaneous T cell lymphoma?
